Published in Pituitary on September 01, 2011
Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med (2013) 0.99
Chorio-retinal thickness measurements in patients with acromegaly. Eye (Lond) (2014) 0.93
Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary (2014) 0.88
Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK. Med Devices (Auckl) (2012) 0.84
Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. Front Endocrinol (Lausanne) (2015) 0.84
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary (2013) 0.84
SAGIT(®): clinician-reported outcome instrument for managing acromegaly in clinical practice-development and results from a pilot study. Pituitary (2016) 0.81
New therapeutic agents for acromegaly. Nat Rev Endocrinol (2015) 0.81
Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS One (2014) 0.80
Assessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study. Contemp Oncol (Pozn) (2013) 0.79
The care continuum in acromegaly: how patients, nurses, and physicians can collaborate for successful treatment experiences. Patient Prefer Adherence (2015) 0.78
Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PLoS One (2013) 0.78
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary (2016) 0.78
Patient-focussed outcomes in acromegaly. Pituitary (2014) 0.77
Multiple facets in the control of acromegaly. Pituitary (2014) 0.76
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest (2014) 0.76
Pharmacoeconomic aspects of the treatment of pituitary gland tumours. Contemp Oncol (Pozn) (2013) 0.76
Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence (2016) 0.75
Short-Term Quality-of-Life Changes after Endoscopic Pituitary Surgery Rated with SNOT-22. J Neurol Surg B Skull Base (2014) 0.75
Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary (2016) 0.75
Surgical management of acromegaly: Long term functional outcome analysis and assessment of recurrent/residual disease. Asian J Neurosurg (2016) 0.75
Treatment Patterns and Economic Burden in Patients Treated for Acromegaly in the USA. Drugs Real World Outcomes (2015) 0.75
Implementing a screening program for acromegaly in Latin America: necessity versus feasibility. Pituitary (2016) 0.75
Body Image Disturbance in Acromegaly Patients Compared to Nonfunctioning Pituitary Adenoma Patients and Controls. Int J Endocrinol (2015) 0.75
Prescription patterns of long-acting somatostatin analogues. SAGE Open Med (2017) 0.75
Retina ganglion cell/inner plexiform layer and peripapillary nerve fiber layer thickness in patients with acromegaly. Int Ophthalmol (2016) 0.75
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary (2017) 0.75
Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34
Medical progress: Acromegaly. N Engl J Med (2006) 6.21
Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev (2004) 3.14
Guidelines for acromegaly management: an update. J Clin Endocrinol Metab (2009) 2.96
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol (2004) 2.25
Epidemiology of acromegaly. Pituitary (1999) 1.91
Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.91
The medical cost of undiagnosed sleep apnea. Sleep (1999) 1.86
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol (2008) 1.82
A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab (2005) 1.51
Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab (1998) 1.48
Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab (2007) 1.47
Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab (2000) 1.41
The cost of health conditions in a health maintenance organization. Med Care Res Rev (2000) 1.40
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care (2008) 1.30
Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab (2008) 1.25
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab (2004) 1.18
Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab (1999) 1.17
Acromegaly and the cardiovascular system. Neuroendocrinology (2006) 1.16
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) (2003) 1.16
AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol (2007) 1.12
ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab (2009) 1.01
Prevalence and pathogenesis of sleep apnea and lung disease in acromegaly. Pituitary (2001) 1.00
Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes (2004) 1.00
Acromegaly. BMJ (2010) 0.97
Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol (2006) 0.95
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol (2008) 0.95
Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs (2009) 0.94
Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest (2004) 0.94
Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) (2002) 0.93
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) (2005) 0.92
Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab (1998) 0.92
Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab (2000) 0.91
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab (2001) 0.91
Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab (2004) 0.91
Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res (2005) 0.91
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol (2008) 0.90
Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinol Invest (2007) 0.90
Acromegalic arthropathy and sleep apnea. J Endocrinol (1997) 0.90
Growth-hormone and prolactin excess. Lancet (1998) 0.89
Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly. Endocr Pract (2007) 0.87
Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) (2005) 0.87
Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord (2009) 0.86
Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol (2007) 0.86
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology (2006) 0.85
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol (Oxf) (1999) 0.84
Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab (1999) 0.83
Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol (Oxf) (2008) 0.83
Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab (2010) 0.83
Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol (2002) 0.83
Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. Eur J Endocrinol (2005) 0.83
Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest (2002) 0.82
Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol (1999) 0.81
Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab (2002) 0.81
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) (2003) 0.80
Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol (2003) 0.80
Excess mortality in acromegaly. Horm Res (2007) 0.79
Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol (2008) 0.79
LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis (2000) 0.78
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res (2009) 0.77
Acromegalic cardiomyopathy: a review of the literature. Pituitary (2003) 0.77
Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet (2001) 7.92
Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet (2001) 4.14
Long-term thyroxine treatment and bone mineral density. Lancet (1992) 3.67
Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab (2006) 3.49
Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1997) 2.90
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab (2008) 2.70
Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf) (1998) 2.59
Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf) (1991) 2.48
Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet (2000) 2.39
A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 2.33
Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab (2000) 2.27
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med (2000) 2.16
Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab (2010) 2.16
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet (2001) 2.08
Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci U S A (1999) 2.04
Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol (Oxf) (1993) 2.00
Clonal origin of pituitary adenomas. J Clin Endocrinol Metab (1990) 1.81
Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol (1999) 1.78
Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab (1998) 1.74
Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med (1999) 1.72
Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. J Clin Endocrinol Metab (1998) 1.72
Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab (1999) 1.69
Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab (1998) 1.68
Colon polyps in acromegaly. Ann Intern Med (1991) 1.66
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab (2008) 1.66
Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol (2001) 1.61
Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment. Br J Gen Pract (1993) 1.57
Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) (1991) 1.57
Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med (2007) 1.56
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone-secreting carcinoid. J Clin Endocrinol Metab (1998) 1.48
The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) (2004) 1.48
Thyroid hormone receptor expression in the "sick euthyroid" syndrome. Lancet (1990) 1.46
An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. Clin Endocrinol (Oxf) (2001) 1.46
Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab (2001) 1.45
Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level. Biochem J (1990) 1.41
Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab (2000) 1.41
Human fetal pituitary expresses functional growth hormone-releasing peptide receptors. J Clin Endocrinol Metab (1998) 1.38
Pathophysiology of acromegaly. Endocr Rev (1983) 1.35
Letter: Metoclopramide and facial dyskinesia. Br Med J (1975) 1.33
Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology (1998) 1.33
Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. BMJ (1996) 1.31
Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig (2007) 1.31
Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med (1998) 1.28
Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med (1990) 1.28
Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev (2000) 1.28
A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care (Engl) (2005) 1.25
Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer. J Clin Endocrinol Metab (2003) 1.24
Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem (2000) 1.24
Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. J Clin Invest (2000) 1.23
Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab (1981) 1.22
Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab (2000) 1.22
Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab (1995) 1.21
Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. Clin Endocrinol (Oxf) (2006) 1.21
Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis. Endocrinology (1998) 1.19
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab (2004) 1.18
Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene. J Clin Endocrinol Metab (1999) 1.18
Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci U S A (1994) 1.18
Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. J Clin Invest (1999) 1.17
Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab (2001) 1.17
Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab (2002) 1.16
Interferon-gamma-induced regulation of peroxisome proliferator-activated receptor gamma and STATs in adipocytes. J Biol Chem (2000) 1.16
Thyroxine replacement treatment and osteoporosis. BMJ (1990) 1.14
Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. QJM (1995) 1.14
Leukemia inhibitory factor (LIF) stimulates proopiomelanocortin (POMC) expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest (1996) 1.14
Expression and compartmentalization of caveolin in adipose cells: coordinate regulation with and structural segregation from GLUT4. J Cell Biol (1995) 1.13
The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology (2000) 1.11
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res (2001) 1.11
Pituitary corticotroph SOCS-3: novel intracellular regulation of leukemia-inhibitory factor-mediated proopiomelanocortin gene expression and adrenocorticotropin secretion. Mol Endocrinol (1998) 1.11
Relative increase in insulin-like growth factor I messenger ribonucleic acid levels in compensatory renal hypertrophy. Endocrinology (1987) 1.11
Pituitary cytokine and growth factor expression and action. Endocr Rev (1997) 1.10
Current management practices for acromegaly: an international survey. Pituitary (2011) 1.10
Somatotroph insulin-like growth factor-I signaling. Ann N Y Acad Sci (1993) 1.09
Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab (1991) 1.07
Management of pituitary tumors. Ann Intern Med (1998) 1.07
Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) (2001) 1.07
Human and murine pituitary expression of leukemia inhibitory factor. Novel intrapituitary regulation of adrenocorticotropin hormone synthesis and secretion. J Clin Invest (1995) 1.07
Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest (1997) 1.06
Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene (2007) 1.06
Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation (1982) 1.05
Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: evidence from live cell imaging. Mol Endocrinol (2000) 1.05
Outcome of surgery for acromegaly--the experience of a dedicated pituitary surgeon. QJM (1999) 1.05
Expression of pituitary tumour transforming gene (PTTG) and fibroblast growth factor-2 (FGF-2) in human pituitary adenomas: relationships to clinical tumour behaviour. Clin Endocrinol (Oxf) (2003) 1.03
Differential expression of oestrogen receptor and oestrogen inducible genes in gastric mucosa and cancer. Gut (1997) 1.02
Licorice inhibits 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels and potentiates glucocorticoid hormone action. Endocrinology (1993) 1.02
The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab (1999) 1.01
Hypothalamic and pituitary leukemia inhibitory factor gene expression in vivo: a novel endotoxin-inducible neuro-endocrine interface. Endocrinology (1996) 1.01
Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res (1994) 1.01
ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab (2009) 1.01
Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet (1996) 1.01
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab (1999) 1.00
Fine needle aspiration cytology in diffuse or multinodular goitre compared with solitary thyroid nodules. BMJ (1993) 1.00
Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res (1995) 1.00
Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling. J Biol Chem (1999) 1.00
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab (1994) 1.00
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab (1995) 1.00
The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest (2001) 1.00
Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells. J Clin Invest (1987) 0.99
Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene (2003) 0.99
Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes (1971) 0.99